Alcobra Ltd said on Tuesday its experimental attention deficit hyperactivity disorder (ADHD) therapy failed a late-stage study in adult patients and the company's shares plunged about 44 percent in premarket trading.
In 2014, Alcobra said it was encouraged by the drug's impact versus a placebo in a separate late-stage adult ADHD trial, after excluding four patients from the analysis, citing "extreme placebo responses." (bit.ly/ZrFCLR) LONDON People recovering from depression but struggling with its effect on memory, concentration and cognitive function may benefit from the stimulant modafinil, according to results of a small study published on Tuesday.
Not everyone is convinced the needle therapy is beneficial for babies.
Reuters is the news and media division of Thomson Reuters.
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms.